Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Recipharm in connection with the public offer from Roar BidCo
Mandate

Vinge advises Recipharm in connection with the public offer from Roar BidCo

December 14, 2020 Capital Markets and Public M&A

Roar BidCo AB has announced a public offer to the shareholders and holders of convertible bonds of Recipharm AB (publ). The offer values all outstanding shares and convertible bonds in Recipharm at approx. SEK 23.6 billion.

The Vinge team includes Erik Sjöman and Linnéa Sellström.

 

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

 Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

 Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

 Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026